ClinicalTrials.Veeva

Menu

A Study of Dapsone Gel in Females With Skin of Color and Acne Vulgaris

Allergan logo

Allergan

Status and phase

Completed
Phase 4

Conditions

Acne Vulgaris

Treatments

Drug: Dapsone Gel

Study type

Interventional

Funder types

Industry

Identifiers

NCT02032407
GMA-ACZ-13-001

Details and patient eligibility

About

This study will evaluate the effect of dapsone gel in female subjects with skin of color (Fitzpatrick Skin Types IV, V, and VI) with acne vulgaris.

Enrollment

68 patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Diagnosis of acne vulgaris
  • Medium to dark complexion (Fitzpatrick Skin Type IV, V or VI)
  • Willing to avoid excessive or prolonged exposure of the face to ultraviolet light (eg, sunlight, tanning beds) throughout the study

Exclusion criteria

  • Received treatment with botulinum toxin of any serotype in the face within 6 months

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

68 participants in 1 patient group

Dapsone Gel
Experimental group
Description:
Dapsone Gel (Aczone®) applied twice daily to the face for 12 weeks.
Treatment:
Drug: Dapsone Gel

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems